Inhibitor Therapeutics (INTI) Total Current Liabilities (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Total Current Liabilities came in at $382320.0 in Q1 2026, up 303.67% YoY from $94712.0 in Q1 2025, and down 50.11% on a QoQ basis from $766330.0 in Q4 2025.
Inhibitor Therapeutics (INTI) Total Current Liabilities (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Total Current Liabilities data on file, last reported at $382320.0 in Q1 2026.
- Quarterly Total Current Liabilities rose 303.67% year-over-year to $382320.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $382320.0 (up 303.67% YoY) and the FY2025 annual result came in at $766330.0, up 7.99% from the prior year.
- Total Current Liabilities retreated to $382320.0 in Q1 2026, from $766330.0 in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $1.1 million in Q3 2022 to a low of $35527.0 in Q2 2024.
- A 5-year average of $405414.9 and a median of $156440.0 in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities slumped 95.31% — and 2026, when it jumped 303.67%.
- Tracing INTI's Total Current Liabilities over 5 years: stood at $678782.0 in 2022, then slipped by 2.01% to $665164.0 in 2023, then advanced by 6.68% to $709618.0 in 2024, then grew by 7.99% to $766330.0 in 2025, then tumbled by 50.11% to $382320.0 in 2026.
- The last three Total Current Liabilities figures came in at $382320.0 (Q1 2026), $766330.0 (Q4 2025), and $87533.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | 174,894.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 382,320.00 |
| Dec 31, 2025 | 766,330.00 |
| Sep 30, 2025 | 87,533.00 |
| Jun 30, 2025 | 139,961.00 |
| Mar 31, 2025 | 94,712.00 |
| Dec 31, 2024 | 709,618.00 |
| Sep 30, 2024 | 44,559.00 |
| Jun 30, 2024 | 35,527.00 |
| Mar 31, 2024 | 155,850.00 |
| Dec 31, 2023 | 665,164.00 |
| Sep 30, 2023 | 156,440.00 |
| Jun 30, 2023 | 43,859.00 |
| Mar 31, 2023 | 78,443.00 |
| Dec 31, 2022 | 678,782.00 |
| Sep 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | 935,019.00 |
| Mar 31, 2022 | 830,214.00 |
| Dec 31, 2021 | 679,630.00 |
| Sep 30, 2021 | 590,892.00 |
| Jun 30, 2021 | 554,859.00 |